




Europe: 30% to 50% of people suffering from schizophrenia are treatment-resistant cases.

They live with highly persistent symptoms.


They require long periods of hospital attention.

They are at greater risk of mortality and multi morbidity.



An innovative disease management system based on mobile technologies

Empower patients with treatment-resistant schizophrenia to better self-manage their condition









The elements of the solution

Smartwatch app for patients



Sensor data collection

Monitor sleep pattern, activity & heart rate

Triggers warning signs

Smartphone app for patients & caregivers



Symptoms, adherence & lifestyle management

Warning signs & coping strategies

Recommendations & motivational feedback

Self-Assessment questionnaires

Messaging system

Web dashboard for the clinicians



Overview of patients data

Clinical assessment

Notes & medical record keeping


Patterns analysis


Predictive analytics

Risk assessment

Recommendations









Additional elements

An application promoting a healthy & active lifestyle to avoid weight gain & type 2 diabetes







Additional elements

Cognitive therapeutic interventions





The benefits of the solution



Improves communication between patients, caregivers, and clinicians



Includes a complete assessment of personal and clinical variables



Defines targeted interventions that mitigate the severity of worsening



Captures multidimensional behavior in real-time in real-world environments



Detects individual Early Warning Signs and offers personalized recommendations







Leading to new treatment protocols





Analyze behavior patterns


First time that a therapeutic

project is based on mHealth

tools for schizophrenic

patients

resistant to treatment





Testimonials

Dr. Iluminada Corripio, Hospital de la Santa Creu i Sant Pau "It is a very innovative project
as it is the first time in Spain and Europe that
work is being done to develop the therapeutic
project for patients with treatment-resistant
schizophrenia

with the help of mobile health tools"



Testimonials

Dr. Asaf Caspi,
Dir.of Ambulatory Psychiatric
Services at the Sheba Medical
Center

"They hope that the m-Resist will prove to be of true benefit for schizophrenic patients by expanding the area of application of personalised pharmacological and psychological treatment, the continuity of the healthcare and the participation of the



Partners

Follow

- www.mresist.eu
- Twitter mResist_eu
- YouTube mResist































This project is co-funded by the Horizon 2020 Framework Programme of the European Union under grant agreement no [643552].

Contact Us

Project Coordinator

Margarita Hospedales Salomo FUNDACIO TICSALUT

Email: mhospedales@ticsalut.cat

Tel.: +34 935532642